Project Grant R01HL176747
Award Date
1/20/25
Completion Date
11/30/29
Dollars Obligated
$385K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $125,568 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Stanford University. The grant supports research to explore the molecular mechanisms governing the import and regulation of NAD+ within the mitochondrial matrix. This work aims to elucidate how mitochondria maintain adequate NAD+ levels and how this process may become dysregulated in heart failure, a major global health issue. The...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $507,096.00 to Wake Forest University Health Sciences to conduct research on the role of mitochondrial calcium signaling in heart failure with preserved ejection fraction (HFPEF). The key objectives are to: Characterize heart cell-specific mitochondrial calcium signaling and functions in HFPEF mouse models, 2) Evaluate the effects...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $771,750 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism after myocardial infarction. The project aims to shed novel insights into how macrophages recruited to the infarcted heart disrupt cardiac muscle metabolism and lead to decreased NAD pools, which play a critical...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $167,400 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Michigan. The 5-year grant, which commenced on May 15, 2025, supports research by Dr. Joshua Meisner, a pediatric cardiologist and physician-scientist, to elucidate the mechanical and metabolic pathways underlying hypertrophic cardiomyopathy (HCM) caused by MYBPC3 gene mutations. The research aims to develop...
The University of Arizona was awarded a $625,316 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the role of RNA methylation and translational regulation in the oxidative stress response of heart failure. The research aims to elucidate how the YTHDF2 protein binds to methylated NRF2 mRNA to selectively induce its translation under oxidative stress, a process that may be impaired in end-stage heart failure. The...
The federal Project Grant award F31HL174083, totaling $145,642.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports research to investigate the molecular mechanisms that regulate the mitochondrial calcium uniporter, a key regulator of mitochondrial function. The goal is to increase understanding of mitochondrial calcium signaling and inform the development of therapies for diseases...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $777,258 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to conduct research focused on unraveling the mechanisms of heart failure in hypertrophic cardiomyopathy. The 5-year project aims to improve understanding of heart failure in hypertrophic cardiomyopathy through novel cardiac magnetic resonance imaging (CMR) phenotyping techniques,...
The federal Project Grant award of $673,642 from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research aims to investigate the role of lysosomes in contributing to arrhythmic risk and sudden cardiac death in ischemic heart failure. The primary objectives are to: 1) Determine whether a lysosomal-sarcoplasmic reticulum (SR) microdomain exists in ischemic heart failure; 2) Evaluate whether TRPML1-mediated lysosomal Ca2+ release can trigger SR...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $634,183 to Loyola University of Chicago to research new mechanisms of cardiac ryanodine receptor (RyR) dysfunction during oxidative stress. The key goals are to: 1) define the molecular mechanisms by which intersubunit cross-linking of RyR activates the channel and disrupts calcium homeostasis during oxidative stress, and 2)...